So how do I dose thi s drug “X”

Preview:

DESCRIPTION

So how do I dose thi s drug “X”. Timothy E Bunchman www.pcrrt.com pcrrt@aol.com. ELIMINATION. I N P U T. Distribution. Re-distribution. D. “Known drug characteristics“. These recommendations made by panel of nephrologists and pharmacists Based on: Protein Binding Information - PowerPoint PPT Presentation

Citation preview

So how do I dose this drug “X”

Timothy E Bunchmanwww.pcrrt.compcrrt@aol.com

PHARMOCOKINETIC COMPARTMENTS

kidneybloodPeripheralliverGI Tract

Distribution Re-distribution

INPUT

ELIMINATION

D. “Known drug characteristics“

• These recommendations made by panel of nephrologists and pharmacists

• Based on:– Protein Binding Information– Volume of Distribution– Molecular Weight

When in doubt, start here…• Blood flow, filter type are not very important.• Find out

– In CVVHD: Dialysate flow rate (ml/hr)• Usually 2 L/1.73m2/hr (33 mL/1.73m2/min)

– In CVVH: Substitution Fluid rate (ml/hr)• Usually 2L/1.73m2/hr (33 mL/1.73m2/min)

• Add this to patient’s native Cr Cl (ml/1.73m2/min)• This is patient’s new Cr Cl dose accordingly• Works in most cases…is good enough for initial

estimates. Follow up with drug level monitoring.

Drug Prescribing in Renal Failureedited by George Aronoff et al

• Commonly carried text by pharmacists

• http://www.kdp-baptist.louisville.edu/renalbook/

• New edition to come out soon• Recommendations for new drugs• IHD and CRRT recommendations• Pediatric recommendations

Great so what do we really do?

• GENERAL PRINCIPLES– kinetics of drugs are based on therapeutic not toxic levels

(therefore kinetics may change)– choice of extracorporeal modality is based on availability,

expertise of people & the properties of the intoxicant in general

– Each Modality has drawbacks– It may be necessary to switch modalities during therapy

(combined therapies inc: endogenous excretion/detoxification methods)

Sieving Coefficients

Solute (MW) Convective Coefficient Diffusion Coefficient

Urea (60) 1.01 ± 0.05 1.01 ± 0.07

Creatinine (113) 1.00 ± 0.09 1.01 ± 0.06

Uric Acid (168) 1.01 ± 0.04 0.97 ± 0.04*

Vancomycin (1448) 0.84 ± 0.10 0.74 ± 0.04**

Calcium (protein bound) 0.67 + 0.1 0.61 + 0.07

Cytokines (large) adsorbed minimal clearance

*P<0.05 **P<0.01

Sieving Coefficient & Protein Binding

Drug Reported SC

Free Fraction

Amikacin 0.93 0.95Imipenem 0.78 0.80Metronidazole

0.84 0.80

Penicillin 0.68 0.50Ranitidine 0.78 0.85Vancomycin 0.80 0.90Valproic Acid 0.22 0.10

Vancomycin

• ~ 1500 Kda• ~ 75 % protein bind

Vancomycin clearance High flux dialysis membrane

0

50

100

150

200

250

0 3 12 15 27 30

Pt 1Pt 2

Time of therapy

Vanc

leve

l (

mic

/dl)

Rx Rx Rx

Rebound Rebound

Carbamazine

• ~ 1500 Kda• ~ 90 % protein bind

0

5

10

15

20

25

30

35

0 5 10 15 20 25 30 35 40

CBZ level(nl < 12)

High flux hemodialysis for Carbamazine Intoxication

Rx

Hrs from time of ingestion

Mic

/ml

Practical ideas

• If you can use a drug that can be monitored (eg vanco, aminoglycosides) then one can look at those kinetics, factor in the X drug molecular weight and protein binding then “best guess” the clearance

• Most vasopressor agents are cleared easily

Conclusion

• Until more data is obtained would err to “over dose” meds that are not nephrotoxic to avoid under dosing

Recommended